Objective: To compare intravenous lidocaine with intravenous amiodarone for ventricular fibrillation resistant to electrical cardioversion.
Methods:
-347 patients were enrolled between Nov 1995 and April 2001 -Study carried out by Toronto Emergency Medical Services -Randomized, double-blinded, placebo controlled trial -Inclusion criteria:
o Out-of-hospital V-fib o V-fib resistant to 3 shocks plus at least one round of IV epinephrine then one more shock and remained in V-fib Or o Recurrent V-fib, after successful initial defibrillation -Exclusion criteria:
o V-fib not due to trauma o V-fib not secondary to a previous different cardiac rhythm -Randomized to either:
o Amiodarone 5mg/kg and lidocaine placebo followed by amiodarone 2.5mg/kg plus placebo if V-fib persisted o Lidocaine 1.5mg/kg and amiodarone placebo followed by another 1.5mg/kg of Lidocaine plus placebo if V-fib persisted -End point = survival to hospital admission to ICU, not survival to ED
Results:
-22.8% of patients in amiodarone group survived to hospital admission -12.0% of patients in lidocaine group survived to hospital admission -For patients with transient ROSC (n=35):
o Amiodarone had higher rate of survival to admission -For patients with no transient ROSC (n=312):
o Amiodarone had higher rate of survival to admission -For patients with V-fib or pulseless V-tach as initial rhythm (n=175): o 24.8% of patients given amiodarone survived to admission o 14.2% of patients given lidocaine survived to admission -Shorter intervals from dispatch of EMS crew to administration of study drug were associated with increased survival to hospital admission Bottom Line: Amiodarone is superior to lidocaine for shock-resistant, out-of-hospital V-fib, in terms of survival to hospital admission. This benefit was seen in all patient subgroups. This study was not powered to show a significant improvement in survival to hospital discharge, and none was seen.
